HCW Biologics (HCWB) EBT Margin (2022 - 2026)
HCW Biologics' (HCWB) quarterly EBT Margin came in at 3849.9% in Q2 2026, up 2558109.0% on a YoY basis from N/an in Q2 2025, and up 77.75% quarter-over-quarter from 17304.52% in Q4 2025.
Powered by 
Analysis
HCW Biologics (HCWB) EBT Margin (2022 - 2026) Analysis & Trends
HCW Biologics (HCWB) has reported EBT Margin for 5 consecutive years, with 3849.9% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBT Margin rose 2558109.0% year-over-year to 3849.9%; the trailing twelve-month figure through Jun 2026 stood at 8249.76% (down 687245.0% YoY), and the FY2025 full-year result was 25828.96%, down 2465587.0% from the prior year.
- EBT Margin advanced to 3849.9% in Q2 2026 per HCWB's latest filing, from 17304.52% in the prior quarter.
- Across five years, EBT Margin topped out at 60.33% in Q1 2022 and bottomed at 43862.27% in Q1 2025.
- Historically, EBT Margin has averaged 8114.31% across 5 years, with a median of 863.18% in 2024.
- The sharpest annual moves came in 2025 and 2026: EBT Margin tumbled 4319718 bps in 2025, then surged 2558109 bps in 2026.
- Over 5 years, EBT Margin stood at 429.49% in 2022, then tumbled by 89 bps to 813.2% in 2023, then decreased by 6 bps to 863.18% in 2024, then plunged by 1905 bps to 17304.52% in 2025, then surged by 78 bps to 3849.9% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 3849.9%, 17304.52%, and 21909.5% for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.38 Bn | 192.39 Bn | 7.24 Bn | 27.53% |
| 2 | Gilead Sciences | 180.22 Bn | 177.04 Bn | 6.22 Bn | -131.41% |
| 3 | Vertex Pharmaceuticals | 131.28 Bn | 123.42 Bn | 2.84 Bn | 41.75% |
| 4 | Regeneron Pharmaceuticals | 81.96 Bn | 73.97 Bn | 3.93 Bn | 35.61% |
| 5 | Argenx Se | 60.49 Bn | 55.30 Bn | 1.37 Bn | 35.78% |
| 6 | Moderna | 53.90 Bn | 48.76 Bn | 52.00 Mn | -528.97% |
| 7 | Alnylam Pharmaceuticals | 33.41 Bn | 30.11 Bn | 992.69 Mn | 13.77% |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 4.84% |
| 9 | Roivant Sciences | 29.08 Bn | 29.08 Bn | 1.16 Mn | -20,427.46% |
| 10 | HCW Biologics | 3.24 Mn | 2.50 Mn | -93,887.00 | -3,849.90% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3,849.90% |
| Dec 31, 2025 | -17,304.52% |
| Sep 30, 2025 | -21,909.50% |
| Jun 30, 2025 | -29,430.99% |
| Mar 31, 2025 | -43,862.27% |
| Dec 31, 2024 | -863.18% |
| Sep 30, 2024 | -917.77% |
| Jun 30, 2024 | -2,471.61% |
| Mar 31, 2024 | -665.09% |
| Dec 31, 2023 | -813.20% |
| Sep 30, 2023 | -606.42% |
| Jun 30, 2023 | -739.56% |
| Mar 31, 2023 | -13,022.01% |
| Dec 31, 2022 | -429.49% |
| Sep 30, 2022 | -223.98% |
| Jun 30, 2022 | -773.36% |
| Mar 31, 2022 | -60.33% |